A venture capital firm founded in China with over $4 billion in total managed assets in the areas of healthcare, technology and internet, and cleantech has invested in more than 70 healthcare companies, that span most sectors of life sciences from pharmaceuticals and medical devices to healthcare IT, diagnostics and select healthcare services.

The firm’s US fund is focused on early-stage health care opportunities in the US with potential market opportunities in China, and the USA team is spread out across multiple locations across the country. The firm intends to lead, co-lead, or co-invest in US-based private companies in biotech for therapeutics, Medtech, and digital health technologies, with equity investments ranging from $5 to $20 million. The firm will not make public company investments.

The firm is open to many sectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm seeks investments in 510K devices and will invest in devices in the PMA pathway depending on stage, preferably clinical or later. In therapeutics, the firm is modality-agnostic but generally seeking opportunities that are past the pre-clinical stage. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. Given the firm’s slogan of “inspiring people with the wisdom to succeed with diligence,” The firm’s team is “hands-on” and typically assumes a board seat after an investment. In general, the firm invests globally and prefers companies that have upside opportunities in China and can leverage the firm’s China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen venture fund based in the US is a flexible investor; the firm’s initial allocations vary depending on the company’s developmental stage, from $150,000 to several million dollars. The firm is open to being a lead investor, and will consider opportunities globally. The firm is open to investing in both privately held companies and publicly traded companies.

The firm invests in the therapeutics sector. The firm only invests in companies with assets that are at the clinical phase of development, and which are based on solidly vetted science. The firm is agnostic in therapeutic indications and will consider opportunities in any area of medicine.

The firm likes to invest as part of a syndicate in science at a US or OUS company that will create a value inflection from a well executed study. The firm has a flexible approach to management teams and may be a more hands-on investor if the management team has limited business experience. The firm requires a high level of transparency from portfolio companies, and guides portfolio companies in planning studies that will create real value inflection points for the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of one of the largest non-profit health systems in the seeks to foster the commercialization of internal ideas as well as external innovation. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off a balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.

The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the health system’s strategic position in the future. Areas of interest include improving the ratings and member retention in our Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.

The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and venture builder based in the USA invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in Infectious Disease technologies to partner and or invest with a current portfolio company. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused Venture Capital and Growth Equity firm currently manages ~$1 billion, providing $15-$50 million of equity capital per company over the life of the investment. With offices in USA and Europe, the firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences venture capital firm based in Canada with additional offices in USA manages over $500M AUM and has invested over $450M in more than 100 companies. With their recent fund closed in 2021, the firm typically makes initial investments ranging from $2-$6 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months, and prioritizes investment opportunities that are based in USA or Canada.

The firm invests primarily in therapeutics and  medical devices, and consumer health technologies. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data. That said, the firm is open to earlier stage, pre-clinical companies with strong validation. The firm is agnostic in terms of modalities.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global biopharmaceutical company with strong interest to invest and collaborate with clinical & early-stage life science companies has significant experience and expertise in conducting drug development and clinical trials in Asia and China, and they are looking to leverage that to partner up with clinical-stage companies. The firm is open to equity investment, licensing-in, co-development and other partnership models. In terms of equity investments, the firm typically engages in seed to series A investment rounds. The initial check size ranges from $1~ 3M with the possibility for follow-on rounds. The firm is generally interested in companies based in the US and Europe and is open to both leading and co-investing.

The firm is interested in therapeutics and medical devices that provide solutions to unmet needs and have strong market potential in Asia and China. Interested indications include chronic, inflammation and aging-related diseases, oncology, and rare diseases. The firm is also interested in rare diseases as long as there are huge unmet needs. The firm is most interested in therapeutics assets that are in Phase I or Phase II clinical stage but can be flexible if the technology is a good fit.

There are no specific requirements for the company’s management team. The firm might consider a board seat on a case-by-case basis. The firm has a strong presence in China and Asia and is willing to support companies with their expertise and experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.